Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Buy” from Analysts

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have received a consensus rating of “Buy” from the five research firms that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $8.80.

CARM has been the subject of a number of research analyst reports. BTIG Research initiated coverage on shares of Carisma Therapeutics in a report on Thursday, April 11th. They issued a “buy” rating and a $6.00 price target for the company. HC Wainwright decreased their price target on shares of Carisma Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd.

Carisma Therapeutics Trading Down 0.6 %

NASDAQ CARM opened at $1.69 on Thursday. The company has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.62. The stock has a market cap of $70.21 million, a P/E ratio of -0.49 and a beta of 0.95. Carisma Therapeutics has a 12-month low of $1.65 and a 12-month high of $9.77. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.01.

Institutional Trading of Carisma Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC acquired a new stake in shares of Carisma Therapeutics in the second quarter worth $47,000. Citigroup Inc. acquired a new stake in Carisma Therapeutics during the second quarter valued at $70,000. California State Teachers Retirement System acquired a new stake in Carisma Therapeutics during the second quarter valued at $78,000. Wells Fargo & Company MN grew its position in Carisma Therapeutics by 1,957.9% during the second quarter. Wells Fargo & Company MN now owns 10,598 shares of the company’s stock valued at $93,000 after buying an additional 10,083 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Carisma Therapeutics by 534.8% during the third quarter. Tower Research Capital LLC TRC now owns 10,982 shares of the company’s stock valued at $46,000 after buying an additional 9,252 shares during the period. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.